Skip to main content
Alex Herrera, MD, Hematology, Duarte, CA

AlexHerreraMD

Hematology Duarte, CA

Hematologic Oncology

Associate Professor of Hematology and Hematopoietic Cell Transplantation

Dr. Herrera is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Herrera's full profile

Already have an account?

  • Office

    1500 Duarte Rd
    Duarte, CA 91010
    Phone+1 626-775-3514
    Fax+1 626-218-5310

Education & Training

  • City of Hope National Medical Center
    City of Hope National Medical CenterFellowship, Blood & Bone Marrow Transplant, 2014 - 2015
  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2012 - 2015
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2009 - 2012
  • Harvard Medical School
    Harvard Medical SchoolClass of 2009
  • Princeton University
    Princeton UniversityA.B., History, Summa Cum Laude, 1999 - 2003

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2014 - 2026
  • MA State Medical License
    MA State Medical License 2011 - 2016
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Larry and Denise Mason Clinical Investigator Career Development Award Lymphoma Research Foundation
  • City of Hope K12 City of Hope Clinical Oncology Career Research Development Program Recipient 2015
  • City of Hope SPORE in Lymphoma Cancer Project Career Enhancement Award Recipient 2015
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Burkitt leukemia limited to the bone marrow has a better prognosis than Burkitt lymphoma with bone marrow involvement in adults  
    Song JY, Venkataraman G, Fedoriw Y, Siddiqi T, Alikhan MB, Kim YS, Murata-Collins J, Weisenburger DD, Liu X, Duffield AS, Leuk Lymphoma, 1/1/2015
  • Ibrutinib in the Treatment of Mantle Cell Lymphoma  
    Herrera AF, Jacobsen EJ, Clin Cancer Res, 1/1/2014

Books/Book Chapters

Abstracts/Posters

  • CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma
    Alex F. Herrera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
    Alex F. Herrera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, a...
    Alex F. Herrera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Future of Maintenance Therapy After Transplant in Relapsed Hodgkin Lymphoma: How Do We Do It Best? 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
  • Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Hodgkin Lymphoma: Beyond ABVD for Everyone 
    60th American Society of Hematology Annual Meeting - 12/1/2018
  • Join now to see all

Press Mentions

  • Nivolumab plus AVD Prolongs PFS in Adolescents and Adults with Advanced-Stage Classic Hodgkin’s Lymphoma
    Nivolumab plus AVD Prolongs PFS in Adolescents and Adults with Advanced-Stage Classic Hodgkin’s LymphomaOctober 29th, 2024
  • Immunotherapy Breakthrough: 92% Survival for Hodgkin Lymphoma Patients
    Immunotherapy Breakthrough: 92% Survival for Hodgkin Lymphoma PatientsOctober 18th, 2024
  • Immunotherapy Extends Survival in Advanced Hodgkin Lymphoma
    Immunotherapy Extends Survival in Advanced Hodgkin LymphomaOctober 18th, 2024
  • Join now to see all

Professional Memberships